Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents
Hypertension. 1985;7:306-310

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohlstein, E. H.
Right arrow Articles by Berkowitz, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohlstein, E. H.
Right arrow Articles by Berkowitz, B. A.

Hypertension, Vol 7, 306-310, Copyright © 1985 by American Heart Association

ARTICLES

Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor

EH Ohlstein and BA Berkowitz

The biochemical mechanism of action of synthetic atrial natriuretic factor (atriopeptin II) was studied in vascular smooth muscle of the rabbit thoracic aorta. Atriopeptin II caused a time-dependent and concentration-dependent increase in tissue levels of cyclic guanosine monophosphate that corresponded in these same tissues with vascular relaxation. The elevation of arterial cyclic guanosine monophosphate levels preceded the onset of vascular relaxation. Atriopeptin II did not alter vascular levels of cyclic adenosine monophosphate. The presence of a functionally intact vascular endothelium was not necessary for atriopeptin II to elicit vascular relaxation. Atriopeptin II-induced vascular relaxation and elevation of cyclic guanosine monophosphate levels were inhibited by the guanylate cyclase inhibitor methylene blue. These data suggest cyclic guanosine monophosphate mediates vascular relaxation produced by atriopeptin II.


This article has been cited by other articles:


Home page
 CirculationHome page
H. Ishii, T. Amano, T. Matsubara, and T. Murohara
Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction
Circulation, December 16, 2008; 118(25): 2710 - 2718.
[Full Text] [PDF]

Home page
 Physiol. Rev.Home page
L. J. Mullins, M. A. Bailey, and J. J. Mullins
Hypertension, Kidney, and Transgenics: A Fresh Perspective
Physiol Rev, April 1, 2006; 86(2): 709 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. M. Pitari, M. D. Di Guglielmo, J. Park, S. Schulz, and S. A. Waldman
Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells
PNAS, July 3, 2001; 98(14): 7846 - 7851.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
A. L. Hyman, B. J. De Witt, B. Gumusel, Q. Hao, P. J. Kadowitz, and H. L. Lippton
L-NAME enhances responses to atrial natriuretic peptide in the pulmonary vascular bed of the cat
J Appl Physiol, June 1, 2001; 90(6): 2101 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Sugimoto, M. Haneda, M. Togawa, M. Isono, T. Shikano, S.-i. Araki, T. Nakagawa, A. Kashiwagi, K.-L. Guan, and R. Kikkawa
Atrial Natriuretic Peptide Induces the Expression of MKP-1, a Mitogen-activated Protein Kinase Phosphatase, in Glomerular Mesangial Cells
J. Biol. Chem., January 5, 1996; 271(1): 544 - 547.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
A. de Bold
Atrial natriuretic factor: a hormone produced by the heart
Science, November 15, 1985; 230(4727): 767 - 770.
[Abstract] [PDF]


Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.